Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 3/20 | 0.33 |
| ▸ | DRD3 | P35462 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12221750 | 0.83 | BRD4 (0.34) | BRD4HSD17B10DRD2DRD3 | |
| SCHEMBL18975217 | 0.80 | DRD2 (0.42) | MEN1ALDH1A1KMT2AL3MBTL1DRD2 | |
| SCHEMBL763968 | 0.80 | DRD2 (0.42) | MEN1ALDH1A1KMT2AL3MBTL1DRD2 | |
| SCHEMBL12438440 | 0.75 | HSD17B10 (0.38) | MEN1ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL12018083 | 0.75 | HSD11B1 (0.31) | ALDH1A1 | |
| SCHEMBL12018136 | 0.73 | HSD11B1 (0.30) | — | |
| SCHEMBL12438437 | 0.72 | HSD17B10 (0.35) | MEN1ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL8860654 | 0.72 | DRD2 (0.47) | MEN1KMT2ABRD4DRD2DRD3 | |
| SCHEMBL636364 | 0.72 | DRD2 (0.47) | MEN1KMT2ABRD4DRD2DRD3 | |
| SCHEMBL17996818 | 0.72 | DRD2 (0.47) | MEN1KMT2ABRD4DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140178302-A1 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING S.P.A. (IT) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140178302-A1 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | ITGA2B, ITGB2, ITGB1 | MEN1 3824/4885ALDH1A1 3450/4885KMT2A 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.